Payment overview · 2025
General Payments
$337.39
13 reported records · 4 companies
Healthcare provider profile · identity verified
Christopher Thompson, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · GLEN MORGAN, WV · NPI 1558730721
Verified facts
What the public records show
CMS Open Payments records show Christopher Thompson, PA-C received $337.39 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 59.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $199.72 | 59.2% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.23 | 24.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.07 | 9.8% | 2 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $23.37 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $337.39 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $180.83 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.23 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| GIAPREZA Normalized: giapreza |
Drug | La Jolla Pharmaceutical Company | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 270 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 61 |
| Lisinopril | Lisinopril | 213 | 58 |
| Omeprazole | Omeprazole | 207 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 62 |
| Losartan Potassium | Losartan Potassium | 179 | 50 |
| Gabapentin | Gabapentin | 169 | 27 |
| Metformin Hcl | Metformin Hcl | 165 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 44 |
| Montelukast Sodium | Montelukast Sodium | 133 | 34 |
| Potassium Chloride | Potassium Chloride | 121 | 39 |
| Furosemide | Furosemide | 117 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 28 |
| Eliquis | Apixaban | 100 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 19 |
| Tramadol Hcl | Tramadol Hcl | 90 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 24 |
| Meclizine Hcl | Meclizine Hcl | 79 | 25 |
| Famotidine | Famotidine | 74 | 20 |
| Glipizide Er | Glipizide | 70 | 23 |
| Buspirone Hcl | Buspirone Hcl | 62 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 17 |
| Ozempic | Semaglutide | 60 | 12 |
| Simvastatin | Simvastatin | 59 | 24 |
| Ibuprofen | Ibuprofen | 57 | 19 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Meloxicam | Meloxicam | 55 | 19 |
| Trazodone Hcl | Trazodone Hcl | 55 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 13 |
| Alprazolam | Alprazolam | 52 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 49 | 13 |
| Finasteride | Finasteride | 45 | 12 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Lorazepam | Lorazepam | 44 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 13 |
| Metformin Hcl Er | Metformin Hcl | 44 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 15 |
| Alendronate Sodium | Alendronate Sodium | 40 | 11 |
| Clonidine Hcl | Clonidine Hcl | 40 | 12 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 33 |
| Atenolol | Atenolol | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 22 |
| Azelastine Hcl | Azelastine Hcl | 23 | 11 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Azithromycin | Azithromycin | 22 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $337.39 · 13 records | AstraZeneca Pharmaceuticals LP | FARXIGA, GIAPREZA, QULIPTA, UBRELVY, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error